+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rituximab"

Rituximab - Global Strategic Business Report - Product Thumbnail Image

Rituximab - Global Strategic Business Report

  • Report
  • March 2026
  • 378 Pages
  • Global
From
CD20 Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Thumbnail Image

CD20 Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 186 Pages
  • Global
From
From
Bullous pemphigoid Market - Global Forecast 2026-2032 - Product Thumbnail Image

Bullous pemphigoid Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 186 Pages
  • Global
From
Autoimmune Drugs - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Drugs - Global Strategic Business Report

  • Report
  • March 2026
  • 287 Pages
  • Global
From
From
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • March 2026
  • 196 Pages
  • Global
From
Systemic Lupus Erythematosus Market - Global Forecast 2026-2032 - Product Thumbnail Image

Systemic Lupus Erythematosus Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 187 Pages
  • Global
From
From
Immunoglobulin a IgA Vasculitis Market Report 2026 - Product Thumbnail Image

Immunoglobulin a IgA Vasculitis Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Dermatomyositis Treatment Market Report 2026 - Product Thumbnail Image

Dermatomyositis Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Rituximab Biosimilars Market Report 2026 - Product Thumbnail Image

Rituximab Biosimilars Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Report 2026 - Product Thumbnail Image

Cancer Monoclonal Antibodies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Scleroderma Diagnostics and Therapeutics Market Report 2026 - Product Thumbnail Image

Scleroderma Diagnostics and Therapeutics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Anti-CD20 Monoclonal Antibodies Market Report 2026 - Product Thumbnail Image

Anti-CD20 Monoclonal Antibodies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Loading Indicator

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs. Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis. The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more